期刊
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
卷 -, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/0300060519877321
关键词
Chronic myeloid leukemia; tyrosine kinase inhibitor; dasatinib; Th1; regulatory T (Treg) cells; CD8(+)T
资金
- International Cooperation and Exchange Program of Science and Technology Department of Sichuan Province [2018HH0114]
- Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital Youth Talent Fund [2017QN03]
- University of Electronic Science and Technology of China Central University Basic Research Expenses Project [2672018ZYGX2018J101]
Objective To investigate the immunomodulatory effects of the tyrosine kinase inhibitor (TKI) dasatinib on T-cell subtypes in patients with chronic myeloid leukemia (CML). Methods T helper (Th) 1, Th2, regulatory T (Treg), and CD8(+)T cell levels were detected in patients with CML (n = 9) before and after dasatinib treatment. The corresponding response level at the time of a blood test was evaluated. Results After dasatinib treatment, six patients achieved a better response level, while three did not show improved response levels. Among the total nine patients, there were no significant differences in Th1, Th2, and Treg cell levels, whereas CD8(+)T cell levels were significantly increased after dasatinib treatment compared with before treatment. When we analyzed the six patients who obtained a better response level, Th1 and CD8(+)T cell levels were significantly increased after dasatinib treatment, but Th2 and Treg cell levels did not change. The other three patients who did not have improved response levels showed decreased Th1 cell levels and increased Treg cell levels after treatment. Conclusions Dasatinib may increase Th1 and CD8(+)T cell levels, and decrease Treg cell levels in patients with CML. This finding might be associated with a good therapeutic response to this drug.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据